Zoetis Inc. (NYSE:ZTS – Free Report) – Research analysts at William Blair reduced their Q1 2025 earnings estimates for shares of Zoetis in a research note issued to investors on Friday, January 31st. William Blair analyst B. Vazquez now expects that the company will post earnings per share of $1.38 for the quarter, down from their prior forecast of $1.45. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q2 2025 earnings at $1.63 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $6.20 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.82 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.70 EPS and FY2026 earnings at $6.92 EPS.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the firm earned $1.36 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year.
Read Our Latest Analysis on Zoetis
Zoetis Stock Down 1.1 %
Shares of NYSE ZTS opened at $170.81 on Monday. Zoetis has a 12-month low of $144.80 and a 12-month high of $200.53. The stock’s fifty day simple moving average is $169.62 and its two-hundred day simple moving average is $179.46. The stock has a market capitalization of $77.06 billion, a PE ratio of 32.11, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.
Institutional Trading of Zoetis
A number of hedge funds have recently added to or reduced their stakes in the stock. Cherry Creek Investment Advisors Inc. raised its holdings in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares in the last quarter. Grove Bank & Trust raised its stake in shares of Zoetis by 0.5% during the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after buying an additional 61 shares in the last quarter. Hancock Whitney Corp lifted its holdings in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares during the period. Strategy Asset Managers LLC lifted its holdings in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares during the period. Finally, VeraBank N.A. boosted its stake in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio is presently 37.59%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- How to Profit From Value Investing
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- EV Stocks and How to Profit from Them
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Quiet Period Expirations Explained
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.